Consumer Marketing briefs

Share this article:
Pharmaceutical manufacturers upped radio spend 137% and Internet advertising spend by a third for the first three quarters of 2009, year-over-year, according to Nielsen data. Overall ad spend for the period was down 4.6% for pharmas, which Nielsen ranked as the No. 2 biggest advertising industry, well behind automotive with $3.2 billion in spending for the period and just ahead of fast food franchises.

Johnson & Johnson's McNeil Consumer put online and offline advertising along with media planning for Motrin and Tylenol in review. Among agencies competing for the assignments is incumbent Deutsch. J&J's Marc Monseau said the reason was “in order to challenge ourselves to have the best possible creative and marketing for our brands.”

GlaxoSmithKline will lend its labs and equipment to test athletes for performance-enhancing drugs at the 2012 Olympic Games in London. GSK, based in the London suburb of Brentford, is partnering with King's College London on the lab, which will be accredited by the World Anti-Doping Agency. 

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?